Lonza, a CDMO, has launched its Media Development Lab at its Singapore site. The offering aims to support bioprocessing customers in optimizing media formulations and facilitating a smooth transition to GMP manufacturing, helping reduce scale-up risk and strengthening long-term supply readiness.
To help address the challenges associated with development timelines and process complexity, the Media Development Lab provides a systematic approach to early media optimization while accounting for scalability, raw material readiness, and GMP manufacturability.
Leveraging Design of Experiments, the service evaluates multiple variables simultaneously to identify key performance drivers, helping to accelerate development timelines, and reduce unnecessary iterations. It combines access to Lonza’s diverse media and feed libraries with manufacturability insights to identify robust, scalable formulations early in development, with structured outputs that define performance ranges and process robustness.
Michael Goetter, Head of Bioscience, Specialized Modalities, Lonza, said, “We are committed to providing customers with the services they need to reduce early-stage risk and select media formulations that are effective at a laboratory scale and simultaneously practical and reliable in manufacturing. Our new Media Development Lab enables us to support customers at the critical front end of their programs, shape formulation strategy, and create a natural pathway into non-GMP and GMP manufacturing.”
